Several reports have shown that abnormal methylation of CpG islands within gene promoters leads to transcriptional silencing and may contribute significantly to the pathogenesis of human leukemias. Hypermethylation of promoters associated with genes involved in the control of the principal late-G1 cell-cycle checkpoint, the apoptotic program and the cell--cell adhesion is detected with increased frequency in acute lymphoblastic leukemia (ALL). 1 This mechanism provides an alternative route to gene mutation of cancer-related genes.
The normal epithelial cell-specific 1 (NES1) gene (also known as kallikrein 10 gene) resides on chromosome 19q and encodes for a secreted serine protease. The physiological function of NES1 is still not clear. The NES1 gene was identified by virtue of its downregulation in breast cancer cell lines, and is considered to be involved in the regulation of normal cell growth. 2 Further experimental evidence suggests that NES1 may function as a tumor suppressor gene. When the NES1 gene was transfected into the tumorigenic breast cancer line MDA-MB-231, its anchorage-independent growth was reduced, and when this cell line was inoculated into nude mice, tumor formation was significantly decreased.
2 Chromosome 19q13.3-4, the region where the NES1 gene resides, is not prone to mutations, deletions or rearrangement in the majority of human cancers. Furthermore, using a luciferase reporter system, it has been found that most tumor cell lines are able to support full or partial transcription from NES1 promoter, suggesting a role of cis-acting mechanisms of the loss of NES1 expression. Hypermethylation of NES1 gene seems to represent one such mechanism, at least, in breast cancer. 3 Although microsatellite markers from this region have shown that 19q is a common site for loss of heterozygosity in childhood ALL, suggesting the presence of at least one tumor suppressor gene at chromosome 19q, 4 the role of the NES1 gene in leukemia has not been studied to date.
Epigenetic inactivation of NES1 gene was studied in four human precursor-B ALL (BV173, TOM . We found a strong reduction of NES1 mRNA in B-precursor ALL cell lines and in 69% of diagnostic ALL samples (Figure 1e ), whereas transcripts of the NES1 gene were detected in normal fresh bone marrow mononuclear cells. By MSP, CpG island of the NES1 exon 3 was revealed to be highly methylated in all ALL cell lines and in 133 of 222 (60%) samples from patients with ALL ( Figure 1a) , which was clearly in contrast to no NES1 methylation in normal cells. All 133 methylated ALLs (100%) showed decreased NES1 expression. In contrast, decreased NES1 expression was detected in only 19 of 89 ALLs with unmethylated pattern (9%). This result indicated that CpG methylation within NES1 exon 3 strongly correlated with decreased constitutive expression of NES1 in ALL cells (Po0.0001). NES1 is one of the few tumor-related genes not containing a canonical CpG island associated with its promoter region, but this region and the 5 0 untranslated region of the gene contain 25 CpG dinucleotides and three CC(A/T)GG motifs. As there are examples in which the methylation of individual CpG sites and CC(A/T)GG motifs in CpG-poor promoters can determine the transcriptional status of a gene, 5 we investigated whether the methylation of the NES1 exon 3 correlated with the methylation of its promoter and 5 0 untranslated regions. The methylation analysis of CpG dinucleotides within these regions was performed by restriction enzyme-mediated PCR (Figure 1b) and MSP (Figure 1d ). Both techniques demonstrated methylation in all ALL cell lines and in those ALL patients who presented NES1 exon 3 methylation. No methylation was observed among patients with unmethylated exon 3. These results indicated that both methods are useful to detect DNA methylation and also that methylation of the NES1 exon 3 correlated perfectly with the methylation in the promoter and untranslated regions. Moreover, PCR with EcoRII-digested DNA showed CC(A/T)GG methylation in 26 of 133 (20%) methylated patients ( Figure 1c) .
As shown in Table 1 , aberrant NES1 methylation was observed similarly in adults (64/105, 61%) and children (69/ 117, 59%). Clinical and laboratory features did not differ significantly between methylated and normal patients. However, methylated patients had a higher relapse rate (52 vs 38%, Po0.05) than nonmethylated patients. Similar results were obtained in the separate analyses of children (relapse rate: 42 vs 27%, P ¼ 0.05) and adults (relapse rate: 64 vs 51%, P ¼ 0.09). We analyzed the DFS among patients who achieved CR according to NES1 methylation. Estimated DFS rates at 10 years were 49.4 and 16.9% for normal and methylated patients, respectively (P ¼ 0.01) (Figure 2 ). Among unmethylated children, the 10-year DFS was 61.3% contrasting with 24.1% for hypermethylated children (P ¼ 0.05, Figure 2) . Among adult ALL patients, the 9-year DFS was 14.3% for methylated cases and 37.3% for normal cases (P ¼ 0.03, Figure 2 ). The actuarial OS calculated for all leukemic patients was 43.1 and 24.7% at 11 years for cases with normal and hypermethylated NES1 gene, respectively (P ¼ 0.08). OS was only significantly different between normal and methylated patients in the separate analysis of adults (29.6 vs 11.7%, P ¼ 0.05) but not in children (57.2 vs 42.2%, P ¼ 0.5). A multivariate analysis of potential prognostic factors demonstrated that the methylation of the NES1 gene was an independent prognostic factor in predicting DFS in the global series and also in adult ALL.
In this study, we have identified NES1 gene as a target gene for methylation and silencing in ALL. NES1 locus methylation was detected in 60% of tumors at diagnosis, suggesting that the inactivation of the NES1 gene is a frequent and early event in the process of tumorigenesis in this disease. Interestingly, an extensive methylation of the NES1 gene was observed affecting not only CpG dinucleotides within its promoter but also CC(A/ T)GG motifs and CpG sites within the 5 0 untranslated and coding regions. Although methylation patterns of promoter regions in tumor suppressor genes have been studied extensively, hypermethylation of CpG islands that are not located in known promoters has been largely overlooked. Not all CpG islands are located in promoters, and it has been demonstrated that hypermethylation of exonic CpG island can occur without concomitant methylation of the promoter or inactivation of the gene itself. 6 Interestingly, by using the quantitative MSSNuPE assay, Nguyen et al 6 have analyzed the methylation levels of promoter and exonic CpG islands of the p15, p16 and PAX6 genes in a series of hematological malignancies and colorectal cancers. Their data suggest that exons with the characteristics of CpG islands are somehow less protected against de novo methylation than those associated with 0 region of the gene. They also showed that de novo methylation of exonic CpG islands occurs concurrently in multiple islands, suggesting global methylation changes in transformed cells. This concurrence of de novo methylation might imply that there is some characteristic common to nonpromoter CpG islands within the body of a gene that render them susceptible to methylation and that such de novo methylation is not gene specific. Our present data provide additional complexity to this theory. In contrast with the results by Nguyen et al, methylation of the NES1 exon 3 was closely correlated with decreasing NES1 expression and was specifically found in ALL samples. Similar results were reported by Lie et al 3 in breast cancer cells. However, these authors were unable to explain the basis for such a strong correlation of a downstream CpG island hypermethylation with a lack of NES1 expression. 3 Our results clearly demonstrate that exon 3 methylation reflects hypermethylation within upstream regions in the NES1 gene, including methylation of CpG and CC(A/T)GG motifs in the promoter and untranslated regions. These data are in agreement with reports that show In the present study, we demonstrated that hypermethylation of the NES1 gene provides important prognostic information in ALL patients. Methylation of the NES1 gene is a factor of poor prognosis in both childhood and adult ALL. Patients with methylation of the NES1 had a poorer DFS than nonmethylated patients. Multivariate analysis confirmed that methylation of the NES1 gene was associated with shorter DFS. However, at present, it is not clear how NES1 might function as a tumor suppressor and might influence the outcome of ALL patients. The primary sequence of NES1 predicted a serine protease. However, Dhar et al 7 were unable to detect this activity using a variety of biochemical approaches. As NES1 is a secreted protein, it probably functions extracellularly as a regulator of cell growth and/or differentiation in an autocrine or paracrine manner. 8 Although additional studies are required to define the biological function of NES1, our present study supports the notion that the NES1 gene is subject to methylation regulation at the transcriptional level in ALL cells, and that this methylation plays a role in the clinical behavior of the disease. 
